UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Find out what would be a good investment for young adults and kickstart your investment journey with confidence.
21,907 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
February brought a sharp drop for Atlassian as investors digested earnings signals and AI risk. This guide breaks dow...
Berkshire Hathaway has resumed stock buybacks, purchasing $15 million of its own shares. CEO Greg Abel personally bou...
A healthcare-focused dividend stock surged last year, outpacing the Nasdaq and delivering solid income. Analysts see ...
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...
A single moment on camera can reveal how perception, risk, and money collide. This piece examines what the mark zucke...
Zevra Therapeutics stock zoomed after a strong earnings release, delivering revenue growth and a first GAAP profit. T...
Salesforce plans up to $25 billion in debt to fund an accelerated share repurchase that would buy back roughly 14% of...
This oddity tech stock is making waves again. With a larger share repurchase plan and improving cash flow, the stock ...
Two durable energy bets stand out in 2026, blending a royalty based producer with a diversified energy fund to weathe...
A Sydney-based tech founder uses AI to design a bespoke cancer vaccine for his dog, Rosie, signaling a new frontier i...
Global gun-control moves through the 1990s to today reshaped crime trends and investor risk. This piece examines outc...